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ABSTRACT
A guinea-pig pneumonia model involving imipenem-susceptible and imipenem-resistant strains of
Acinetobacter baumannii was developed to assess the in-vitro and in-vivo activities of imipenem, alone or
in combination with amikacin, and the pharmacokinetic and pharmacodynamic parameters. Serum
levels were measured by bioassay (imipenem) or immunoassay (amikacin), followed by calculation of
pharmacokinetic and pharmacodynamic parameters (Cmax, AUC, t1 ⁄ 2, Cmax ⁄MIC, AUC ⁄MIC, and
Dt ⁄MIC). In-vivo efﬁcacy was evaluated by comparing bacterial counts in the lungs of treatment groups
with end-of-therapy controls by ANOVA and post-hoc tests. Decreases in the Cmax (13.4%), AUC (13%),
t1 ⁄ 2 (25%) and Dt ⁄MIC (11.8–32.2%) of imipenem were observed when it was administered with
amikacin, compared with administration of imipenem alone. Similarly, decreases in the Cmax (34.5%),
AUC (11.6%), Cmax ⁄MIC (34.5%) and AUC ⁄MIC (11.7%) of amikacin were observed when it was
administered with imipenem. Bacterial counts in lungs were reduced by imipenem (p 0.004) with the
imipenem-susceptible strain, and by amikacin (p 0.001) with the imipenem-resistant strain. The
combination of imipenem plus amikacin was inferior to imipenem alone with the imipenem-susceptible
strain (p 0.01), despite their in-vitro synergy, and was inferior to amikacin alone with the imipenem-
resistant strain (p < 0.0001). In summary, combined use of imipenem with amikacin was less efﬁcacious
than monotherapy, probably because of a drug–drug interaction that resulted in decreased pharma-
cokinetic and pharmacodynamic parameters for both antimicrobial agents.
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INTRODUCTION
Treatment of nosocomial infections caused by
Acinetobacter baumannii is of major concern for
clinicians. The natural resistance ofA. baumannii to
adverse environmental conditions, combined with
its ability to develop resistance to multiple anti-
microbial agents, gives this organism all the
properties necessary to be a successful nosocomial
pathogen [1,2]. Nosocomial pneumonia is the
most frequent infection caused by A. baumannii,
accounting for 15–24% of all episodes of ventila-
tor-associated pneumonia at some institu-
tions [3,4]. Pneumonia is the major source of
A. baumannii bacteraemia, and is associated with
increased mortality [5,6]. Combination therapy
with a b-lactam plus an aminoglycoside is consid-
ered the best choice for the treatment of severe
infections caused by Gram-negative bacilli [7,8].
However, no controlled clinical studies have been
performed to examine this approach with respect
to infections caused by A. baumannii. Imipenem
has been considered the treatment of choice for
A. baumannii pneumonia [9,10], but is gradually
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losing activity against an increasing number of
A. baumannii isolates at many institutions [11,12].
The aims of the present study were to compare
the in-vitro and in-vivo activities of imipenem
in the treatment of experimental pneumonia
induced by multiresistant strains of A. baumannii
with different susceptibilities to carbapenems,
and to assess the possible in-vivo therapeutic
beneﬁt of combining imipenem with amikacin.
For this purpose, a model of A. baumannii acute
pneumonia was developed in immunocompetent
guinea-pigs.
MATERIALS AND METHODS
Bacteria
Two multiresistant strains of A. baumannii, isolated originally
from the respiratory tract specimens of two patients with
nosocomial pneumonia, were used. Both strains were identi-
ﬁed by the MicroScan system (Baxter Diagnostics, Deerﬁeld,
MA, USA), the API 20NE system (bioMe´rieux, Marcy L’Etoile,
France) and growth tests [13]. Both strains were used to induce
acute pneumonia in the experimental model (see below). The
ﬁrst strain (SS) was susceptible to imipenem and amikacin
(MICs ⁄MBCs of 1 ⁄ 2 and 4 ⁄ 8 mg ⁄L, respectively), while the
second strain (RS) was resistant to imipenem and susceptible
to amikacin (MICs ⁄MBCs of 16 ⁄ 64 and 4 ⁄ 4 mg ⁄L, respect-
ively). Both strains were resistant to piperacillin, ampicillin,
ticarcillin, amoxycillin–clavulanate, piperacillin–tazobactam,
ceftriaxone, cefotaxime, ceftazidime, aztreonam, gentamicin,
tobramycin, netilmicin, oﬂoxacin and ciproﬂoxacin.
Animals
Dunkin–Hartley female guinea-pigs (250–300 g) were used for
in-vivo studies. These were certiﬁed pathogen-free and were
assessed for genetic authenticity.
Drug pharmacokinetics and pharmacodynamics
Antimicrobial agents were laboratory standard powders and
were used immediately after being dissolved and diluted.
Serum levels of imipenem (Merck Sharp & Dohme, Madrid,
Spain) and amikacin (Normon SA, Madrid, Spain) were
measured after a single intramuscular injection in the thigh
of the animals, following administration either alone (imipe-
nem 60 mg ⁄ kg or amikacin 15 mg ⁄kg) or in combination (at
the same dosages, with each drug in opposite thighs). Blood
was taken from anaesthetised guinea-pigs by intracardiac
needle-aspiration after 10, 15, 30, 60, 90, 120 and 150 min, with
groups of three animals for each time-point.
Drug concentrations in sera were measured by bioassay for
imipenem [14] and by immunoassay for amikacin (Emit
Amikacin Test; Syva, Cupertino, CA, USA) [15]. The bioassay
used Micrococcus luteus strain ATCC 9341 as the reference
standard; the standard curve of imipenem was a straight line
for the range 0.25–2 mg ⁄L, and was used to calculate the
imipenem concentrations in guinea-pig serum samples by the
linear regression model. For determining imipenem levels
after combined administration, and in order to inactivate
amikacin, polyanetholesulphonic acid 1% w ⁄v (Sigma Chem-
ical Co., St Louis, MO, USA) was added before the bioassay
was performed [16].
The detection limit, intra- and inter-assay variability, and
lineality for imipenem were 0.09, 0.93, 7.36 and 0.96 mg ⁄L,
respectively. The maximum concentration (Cmax; mg ⁄L), area
under the concentration–time curve (AUC; mg.h ⁄mL) and
terminal half-life (t1 ⁄ 2; h) were then calculated using the
program PKCALC [17]. The pharmacodynamic (PD) parame-
ters known to correlate with the in-vivo efﬁcacy of the
antimicrobial agents were calculated for both strains [18].
Thus, the time above MIC (Dt ⁄MIC, h) was calculated for
imipenem by the construction of a regression line on the
concentration–time curve, using the method of Frimodt-Mo¨ller
et al. [19], and the Cmax ⁄MIC and the AUC ⁄MIC (h) ratios were
calculated for amikacin.
In-vitro studies
MICs and MBCs were measured by the tube dilution method
with geometric two-fold serial dilutions of the antimicrobial
agents (ranging from 0.06 to 128 mg ⁄L) in Mueller-Hinton II
Broth Cation-Adjusted (MHBCA; Becton-Dickinson, Cockeys-
ville, MD, USA) and a ﬁnal inoculum of 5 · 105 CFU ⁄mL.
Quantiﬁcation of the initial inoculum and bacterial growth
was by subculture on blood agar plates (Agar-Sangre
Columbia; Becton Dickinson) incubated for 18–24 h at 37C
in air. Escherichia coli ATCC 25922 and Staphylococcus aureus
ATCC 29213 were used as control strains. The MIC and MBC
were deﬁned as the lowest concentration of antibiotic at
which no growth was visible, and the concentration that
resulted in the killing of 99.9% of the original inoculum,
respectively [20].
The bactericidal activity of antibiotics was assessed by time-
kill curves [21]. Tubes containing 20 mL of MHBCA without
antibiotics (controls), and with concentrations of each antibi-
otic equivalent to the Cmax reached in guinea-pig plasma, were
inoculated separately with an aliquot from a 6-h culture of the
SS and RS strains to give a ﬁnal density of 5 · 105 CFU ⁄mL.
Bacterial growth in tubes was assessed after incubation for 0, 2,
4, 8 and 24 h at 37C by subculturing 100-lL aliquots on blood
agar plates and incubating for 24 h at 37C.
The synergy of antimicrobial combinations was evaluated
by the chequerboard technique, with concentrations of both
antimicrobial agents ranging from 0.0625 to 1 · MIC [22].
Fractional inhibitory concentrations (FICs) of the antimicrobial
agents were calculated as follows: the FIC of drug A
(FICA) = (MIC of drug A in combination ⁄MIC of drug
A alone); similarly, the FIC of drug B (FICB) = (MIC of drug
B in combination ⁄MIC of drug B alone). The sum of both FICs
(SFIC = FICA + FICB) was used to classify the combination as
synergistic (SFIC £ 0.5), partially synergistic (SFIC > 0.5 and
< 1), additive (SFIC = 1), indifferent (SFIC > 1 and £ 4) or
antagonistic (SFIC > 4) [22].
The pneumonia model
Pneumonia was induced by the Esposito and Pennington
technique [23]. Guinea-pigs were anaesthetised by an intra-
peritoneal injection of ketamine (Ketolar; Parke-Davis, Barce-
lona, Spain) 100 mg ⁄ kg and a subcutaneous injection of
lidocaine (Lincaı´na 5%; Braun Medical, Barcelona, Spain)
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0.2 mL in the anterior portion of the neck. After aseptic
surgical exposure of the cervical trachea, 0.25 mL of bacterial
suspension was introduced slowly by trans-tracheal inocula-
tion with a 25G needle. The neck incision was then surgically
sutured and, ﬁnally, the animals were held in a vertical
position for 1 min to ensure efﬁcient distribution of the
inoculum into both lungs.
The inoculum was measured in every experiment for both
strains. First, a bacterial suspension was prepared by culture
for 4 h in trypticase soy broth (TSB; Becton-Dickinson). The
ﬁnal inoculum was obtained by centrifuging 50 mL of the TSB
culture and resuspending the bacterial pellet in 10 mL of TSB.
Finally, the concentrated bacterial suspension was mixed with
10 mL of porcine mucin solution (Sigma Chemical Co.),
diluted to 10% v ⁄v in saline solution, in order to increase
pathogenicity [24].
Two groups of six guinea-pigs were inoculated with the SS
and RS strains, respectively, and then killed humanely after
4 h in order to conﬁrm the development of pneumonia. For
each group, the lungs of four animals were processed for
microbiological studies, and those of the remaining two
animals for histological studies.
Treatment
Animals were treated for 24 h, starting 4 h after bacterial
challenge. Imipenem was administered intramuscularly at
60 mg ⁄ kg, three-times-daily, while amikacin was administered
intramuscularly at 15 mg ⁄ kg four-times-daily. These dosages
were chosen according to the results of pharmacokinetic (PK)
studies and PD parameters (Dt ⁄MIC for imipenem and
Cmax ⁄MIC for amikacin). Eight groups of animals were
evaluated, four inoculated with the SS strain and four with
the RS stain. Twelve animals were assigned to each treatment
group (control without treatment; treatment with imipenem or
amikacin alone; and treatment with imipenem + amikacin).
Animals in combination groups received imipenem and
amikacin in opposite thighs in order to avoid drug interactions
at the site of injection.
The guinea-pigs were killed humanely 4 h after the last
dose (including the control groups, which were designated as
end-of-therapy controls) and the thoracic wall was opened
aseptically to expose the lungs and mediastinum. The lungs
and heart were extracted en bloc, after which both lungs were
separated and weighed. Lung tissue was processed for
quantitative culture as described previously [24].
To assess any potential toxicity of the antimicrobial agents,
three groups of 12 healthy guinea-pigs were given imipenem,
amikacin, or imipenem + amikacin at the same dosages and
intervals as the treatment groups for 72 h. Toxicity was
assessed by evaluating survival rates 5 days after the ﬁrst
dose of antibiotics.
Statistical analysis
Quantitative lung cultures (CFU ⁄g ± SD) of the control and
treatment groups were analysed. The ANOVA test and post-hoc
tests (Tukey and Dunnet) were used for group comparisons.
The sizes of the groups were designed to detect a difference of
1.5 log10 CFU ⁄ g of lung tissue culture with a and b errors of
0.05 and 0.2, respectively. The correlation between PD
(Cmax ⁄MIC, AUC ⁄MIC and Dt ⁄MIC) and in-vivo efﬁcacy
parameters was assessed using Pearson’s r coefﬁcient. For this
purpose, treatment groups were divided into those in which
imipenem was used and those in which amikacin was used. A
p value of < 0.05 was considered signiﬁcant.
RESULTS
In-vitro studies
Both antimicrobial agents showed bactericidal
activity against the SS strain. Against the RS
strain, imipenem showed bactericidal activity at
24 h, despite the relatively high imipenem MIC,
but amikacin was not bactericidal. The observed
discrepancy with imipenem probably reﬂects the
different techniques used to determine MIC
(broth microdilution) and bactericidal activity
(time-kill curves). Results obtained with these
two techniques are not directly comparable.
The combination of imipenem + amikacin demon-
strated synergy against the SS strain, with
SFIC = 0.156 (with imipenem at 0.125 · MIC,
and amikacin at 0.25 · MIC), and SFIC = 0.375
(with imipenem at 0.25 · MIC, and amikacin at
0.125 · MIC). The combination was indifferent
(SFIC = 2) against the RS strain.
Drug PK and PD parameters
PK and PD parameters for each drug (adminis-
tered alone or in combination) are shown in
Tables 1 and 2. A reduction in all PK and PD
parameters of imipenem was observed when
imipenem was administered in combination with
amikacin. Reductions in Cmax (13.4%), AUC
(13%) and t1 ⁄ 2 (25%) led to decreases in Dt ⁄MIC
(11.8–32.2%). Similarly, reductions in Cmax
(34.5%) and AUC (11.6%) for amikacin were
observed when amikacin was administered in
combination with imipenem; these reductions
resulted in subsequent reductions in Cmax ⁄MIC
(34.5%) and AUC ⁄MIC (11.7%).
Table 1. Pharmacokinetic parameters of imipenem and
amikacin administered alone or in combination, showing
the differences (%) with respect to the values reached after
their independent administration
Antimicrobial agent
Doses
(mg ⁄kg)
Cmax
(mg ⁄L)
AUC
(mg.h ⁄L)
t1 ⁄ 2
(h)
Imipenem 60 21.6 23 0.5
Imipenem (+ amikacin)a 60 18.7 () 13.4) 20 () 13) 0.375 () 25)
Amikacin 15 33 30.8 0.54
Amikacin (+ imipenem)a 15 21.6 () 34.5) 27.2 () 11.6) 0.9 (+ 66)
aCombined pharmacokinetics.
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Characteristics of the pneumonia model
Both strains of A. baumannii were isolated from
the lungs of every group, with counts of
8.21 ± 0.60 and 8.63 ± 0.48 CFU ⁄g of lung for
the SS and RS strains, respectively. Histopatho-
logical studies of lungs from animals inoculated
with the SS strain showed bilateral and multifocal
areas of severe acute inﬂammatory inﬁltration of
polymorphonuclear cells, mainly in peribronchial
and perivascular spaces, with extensive areas of
haemorrhagic necrosis. Similarly, the lungs of
animals inoculated with the RS strain showed
acute inﬂammatory alterations, although no nec-
rosis was evident, moderate-to-severe congestion
in vessels and alveolar septa, scarce areas of
alveolar haemorrhage, and acute bronchitis with
focal necrosis of the bronchial wall.
In-vivo efﬁcacy of antimicrobial treatment
The in-vivo efﬁcacy parameters of the different
treatments are detailed in Tables 3 and 4. Most
animals survived the surgical procedure for > 4 h,
and 83.3–100% survived during the 24-h treat-
ment period. In groups inoculated with the SS
strain, imipenem was the only treatment that
reduced bacterial counts in lungs with respect to
controls (6.11 ± 0.61 vs. 6.92 ± 0.55 CFU ⁄g;
p 0.004); the combinations of imipenem + amika-
cin were inferior to monotherapy with imipenem
(6.89 ± 0.29 vs. 6.11 ± 0.61 CFU ⁄ g; p 0.01). In
groups inoculated with the RS strain, amikacin
was the only treatment that reduced the bacterial
counts in lungs (5.35 ± 0.45 vs. 7.31 ± 1.14 CFU ⁄g;
p 0.01). Amikacin achieved a signiﬁcantly higher
bacterial count reduction in lungs than did imi-
penem + amikacin (5.35 ± 0.45 vs. 6.59 ± 0.22
CFU ⁄ g; p 0.0001). All animals in the toxicity
control groups survived.
No correlation was found between the Dt ⁄MIC
of imipenem and the in-vivo efﬁcacy parameters.
A negative correlation was found between the
Cmax ⁄MIC (Pearson’s r = ) 0.22; p 0.03) and the
AUC ⁄MIC (Pearson’s r = ) 0.2; p 0.03) of amika-
cin and the bacterial counts in lungs from treat-
ment groups receiving amikacin.
DISCUSSION
This study developed a new discriminative model
with low mortality rates for acute pneumonia
Table 2. Pharmacodynamic param-
eters of imipenem and amikacin
administered alone or in combina-
tion, showing the differences (%)
with respect to the values reached
after their independent administra-
tion
Antimicrobial agent
Doses
(mg ⁄kg)
Cmax ⁄MIC AUC ⁄MIC (h) Dt ⁄MIC (h)
SS RS SS RS SS RS
Imipenem 60 NA NA NA NA 2.28 0.93
Imipenem (+ amikacin) 60a NA NA NA NA 2.01 () 11.8) 0.63 () 32.2)
Amikacin 15 8.2 8.2 7.7 7.7 NA NA
Amikacin (+ imipenem) 15a 5.4 () 34.5) 5.4 () 34.5) 6.8 () 11.7) 6.8 () 11.7) NA NA
SS, carbapenem-susceptible strain; RS, carbapenem-resistant strain; NA not applicable.
aCombined pharmacokinetics.
Table 3. Comparative efﬁcacies of
imipenem, amikacin and the combi-
nation in groups of guinea-pigs
inoculated with a carbapenem-sus-
ceptible strain
Treatment
Animals
(no.)
Inoculum
(log CFU ⁄mL)
Survival from
surgery Survival (%)
Lung cultures
(log CFU ⁄ g, mean ± SD)
Controls 12 9.52 12 11 (91.7) 6.92 ± 0.55
Imipenem 12 9.59 10 10 (100) 6.11 ± 0.61a
Amikacin 12 9.07 12 10 (83.3) 6.58 ± 0.56
Imipenem + amikacin 11 9.56 10 10 (100) 6.89 ± 0.29b
ap 0.004 vs. control group; bp < 0.05 vs. imipenem group.
Table 4. Comparative efﬁcacies of
imipenem, amikacin and the combi-
nation in groups of guinea-pigs
inoculatedwith a carbapenem-resist-
ant strain
Treatment
Animals
(no.)
Inoculum
(log CFU ⁄mL)
Survival from
surgery Survival (%)
Lung cultures
(log CFU ⁄ g, mean ± SD)
Control 12 9.47 12 10 (83.3) 7.31 ± 1.14
Imipenem 12 9.47 8 7 (87.5) 6.77 ± 0.32a
Amikacin 12 9.74 10 10 (100) 5.35 ± 0.45b
Imipenem + amikacin 12 9.34 10 9 (90) 6.59 ± 0.22a
ap < 0.05 vs. amikacin group; bp < 0.05 vs. control group.
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caused by multiresistant A. baumannii in immu-
nocompetent guinea-pigs. Trans-tracheal inocula-
tion of bacteria was followed by the development
of bilateral pneumonia in all animals, thereby
resembling the pathogenesis of A. baumannii
pneumonia in humans, and resulted in high
bacterial concentrations in lungs at 28 h following
inoculation. The model demonstrated that imipe-
nem was the only treatment which reduced
bacterial concentrations in the lungs of guinea-
pigs inoculated with the SS strain of A. baumannii,
while only amikacin reduced bacterial concentra-
tions in the lungs of guinea-pigs inoculated with
the RS strain. In both cases, the combination of
imipenem + amikacin was inferior to monothera-
py, despite demonstrated in-vitro synergy. A
drug–drug interaction was apparent between
imipenem and amikacin when they were used
in combination in the in-vivo experiments, with a
decrease in the Dt ⁄MIC of imipenem and the
Cmax ⁄MIC of amikacin. The decline in these key
PD parameters could explain the absence of any
in-vivo beneﬁt of the combination in comparison
to monotherapy.
A correlation was found between the Cmax ⁄
MIC of amikacin and its in-vivo efﬁcacy param-
eters. As already known, Cmax ⁄MIC is a key
predictor of the antibacterial activity of amino-
glycosides, and there is consensus that it should
reach a value of ‡ 8 in order to ensure clinical
efﬁcacy [18]. In the present study, the Cmax ⁄MIC
ratios were 8.4 in groups treated with amikacin
monotherapy, and 5.4 in groups treated with
imipenem + amikacin. In addition, the AUC ⁄
MIC of amikacin correlated with a reduction in
bacterial counts in the lungs of animals treated
with amikacin. This latter parameter is also
known to be a reliable predictor of the clinical
efﬁcacy of aminoglycosides [18]. However, no
signiﬁcant correlation was found between the
Dt ⁄MIC of imipenem and its in-vivo efﬁcacy
parameters. This was surprising, considering that
a Dt ⁄MIC of at least 30–40% of dosing intervals
correlates strongly with the antibacterial activity
of b-lactams [18]. With respect to carbapenems,
even a lower Dt ⁄MIC (25–30%) could be enough
to ensure in-vivo efﬁcacy [18,25]. The low
Dt ⁄MIC of imipenem in the groups inoculated
with the RS strain (11.6%), and the drug–drug
interaction, which conditioned reductions in this
PD parameter for groups treated with the com-
bination, could account for the lack of correlation
between Dt ⁄MIC and the in-vivo activity of
imipenem.
The results obtained in the present study were
similar to those observed in the treatment of other
experimental infections caused by A. baumannii
[24,26]. Several possibilities could explain the
observed drug–drug interaction. It is already
known that aminoglycosides interact chemically
with b-lactams [27,28]. This reaction results in
the opening of the b-lactam ring and acylation of
the amino group of the aminoglycoside, and the
subsequent loss of activity of both. For this
reason, these different types of antimicrobial
agents should not be mixed in the same solution
before infusion. However, in the present study,
the antimicrobial agents were prepared independ-
ently and were injected into opposite thighs in
order to avoid any interaction at the injection site.
In addition, an interaction in the PK process is
unlikely, knowing the PK of imipenem and
amikacin [25,29], given that the reduction of
virtually all PK parameters of both drugs would
imply interactions in various steps (absorption,
distribution, metabolism and excretion) of the PK
proﬁle. Therefore, it seems that the most likely
explanation would be an in-vivo chemical inter-
action between the two antimicrobial agents,
which would occur both in intravascular and
extravascular compartments, thereby determining
a decrease in PD parameters and a subsequent
loss of activity of both antimicrobial agents. Such
an in-vivo interaction has also been observed in
anephric animals following administration of
carbenicillin for 24 h in combination with differ-
ent aminoglycosides [30].
There have been few studies on the clinical
importance of such drug–drug interactions. Sev-
eral studies have demonstrated different rates of
aminoglycoside inactivation by different b-lactams
(carbenicillin, ticarcillin, moxalactam) in patients
treated topically or systemically [31,32], in healthy
volunteers [33], or in volunteers with chronic
renal failure [34,35]. Other studies failed to
demonstrate any clinical beneﬁt when combina-
tions of b-lactams plus aminoglycosides were
compared with b-lactam monotherapy for the
treatment of severe infections caused by Gram-
negative bacilli [36–38]. Further clinical studies
analysing combined treatment with b-lactams and
aminoglycosides, focusing speciﬁcally on clinical
PK ⁄PD parameters, are needed to elucidate this
issue fully.
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